GlassScriptPhysician profile
Randa Duke
NPI 1124360193
$2,291.66
in general payments reported to CMS, 2019-2025
24 companies · $528 in 2025
The $528 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $376 · 2022: $447 · 2023: $399 · 2024: $541 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $390.65 | 2021-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $273.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $203.81 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $202.87 | 2021-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $94.39 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $78.97 | 2024-2025 | Voquezna |
| Pfizer INC. | $73.27 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $71.88 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $55.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.17 | 2025 | |
| Exact Sciences Corporation | $36.98 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $35.06 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.10 | 2022-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.67 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.78 | 2024 | Sunosi |
| Abbott Laboratories | $23.46 | 2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $20.04 | 2022 | |
| Astellas Pharma US INC | $18.58 | 2023 | Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $15.83 | 2023 | Seglentis |
| Currax Pharmaceuticals LLC | $14.85 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.16 | 2025 | |
| Eisai INC. | $13.50 | 2021 | |
| Genentech USA, INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randa Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.